<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from N/A to N/A
--- ---
Commission File No. 814-55
TECHNOLOGY FUNDING VENTURE PARTNERS IV, AN AGGRESSIVE GROWTH FUND, L.P.
-----------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 94-3054600
------------------------------ ---------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2000 Alameda de las Pulgas, Suite 250
San Mateo, California 94403
------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
(650) 345-2200
--------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
--- ---
No active market for the units of limited partnership interests
("Units") exists, and therefore the market value of such Units cannot be
determined.
<PAGE>
I. FINANCIAL INFORMATION
Item 1. Financial Statements
BALANCE SHEETS
--------------
<TABLE>
<CAPTION>
(unaudited)
June 30, December 31,
2000 1999
----------- -----------
<S> <C> <C>
ASSETS
Investments:
Equity investments (cost basis of
$11,593,816 and $11,915,314 for 2000
and 1999, respectively) $14,333,188 15,419,719
Notes receivable, net (cost basis of
$3,002,327 and $221,307 for 2000 and
1999, respectively) 2,030,348 221,307
---------- ----------
Total investments 16,363,536 15,641,026
Cash and cash equivalents 407,775 677,285
Other assets 4,999 1,454
---------- ----------
Total assets $16,776,310 16,319,765
========== ==========
LIABILITIES AND PARTNERS' CAPITAL
Accounts payable and accrued expenses $ 26,924 54,345
Due to related parties 21,712 68,554
Other liabilities 5,048 9,789
---------- ----------
Total liabilities 53,684 132,688
Commitments, contingencies and
subsequent events (Notes 2, 3, 4 and 8)
Partners' capital:
Limited Partners (400,000 Units
outstanding) 17,687,258 15,915,048
General Partners (964,632) 272,029
---------- ----------
Total partners' capital 16,722,626 16,187,077
---------- ----------
Total liabilities and partners'
capital $16,776,310 16,319,765
========== ==========
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
STATEMENTS OF OPERATIONS (unaudited)
-----------------------------------
<TABLE>
<CAPTION>
For the Three For the Six
Months Ended Months Ended
June 30, June 30,
------------------------- ----------------------
2000 1999 2000 1999
---- ---- ---- ----
<S> <C> <C> <C> <C>
Income:
Notes receivable interest $ 260,297 10,836 290,978 21,120
Short-term investment interest 6,760 1,252 15,911 7,384
---------- --------- --------- -------
Total income 267,057 12,088 306,889 28,504
Costs and expenses:
Management fees 76,252 40,385 117,051 83,070
Individual General Partners'
compensation 18,131 11,337 23,728 20,006
Operating expenses:
Investment operations 223,957 65,611 279,433 144,369
Administrative and investor services 147,325 181,491 259,361 319,141
Professional fees 32,603 49,889 52,725 61,749
Computer services 33,247 30,478 66,865 58,914
Interest expense -- -- 3,732 --
---------- --------- --------- -------
Total operating expenses 437,132 327,469 662,116 584,173
---------- --------- --------- -------
Total costs and expenses 531,515 379,191 802,895 687,249
---------- --------- --------- -------
Net operating loss (264,458) (367,103) (496,006) (658,745)
Net realized gain (loss) from
sales of equity investments -- -- 3,402,598 (30,464)
Realized gain from venture capital
limited partnership investments 331,026 60,692 680,264 126,968
Realized losses from investment
write-downs -- (2,615) -- (2,615)
---------- --------- --------- -------
Net realized income (loss) 66,568 (309,026) 3,586,856 (564,856)
Change in net unrealized fair value:
Equity investments (11,447,839) 1,352,222 (765,033) 688,448
Notes receivable (971,979) -- (971,979) --
---------- --------- --------- -------
Net (loss) income $(12,353,250) 1,043,196 1,849,844 123,592
========== ========= ========= =======
Net (loss) income per Unit $ (24.56) 2.06 4.43 0.25
========== ========= ========= =======
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
STATEMENTS OF CASH FLOWS (unaudited)
-----------------------------------
<TABLE>
<CAPTION>
For the Six Months Ended June 30,
--------------------------------
2000 1999
---------- ----------
<S> <C> <C>
Cash flows from operating activities:
Interest received $ 17,558 16,015
Cash paid to vendors (223,156) (215,259)
Cash paid to related parties (658,556) (367,555)
Interest paid on short-term
borrowings (3,732) --
--------- ---------
Net cash used by operating activities (867,886) (566,799)
--------- ---------
Cash flows from investing activities:
Purchase of equity investments (350,617) (698,868)
Notes receivable issued (2,500,000) (183,333)
Repayments of notes receivable 6,836 198,844
Proceeds from sales of equity
investments 4,537,633 68,372
Distributions from venture capital
limited partnership investments 218,819 --
--------- ---------
Net cash provided (used) by
investing activities 1,912,671 (614,985)
--------- ---------
Cash flows from financing activities:
Distributions to General Partners (1,314,295) --
--------- ---------
Net cash used by financing
activities (1,314,295) --
--------- ---------
Net decrease in cash
and cash equivalents (269,510) (1,181,784)
Cash and cash equivalents at
beginning of year 677,285 1,188,918
--------- ---------
Cash and cash equivalents $ 407,775 7,134
at June 30 ========= =========
See accompanying notes to unaudited financial statements.
</TABLE>
<PAGE>
STATEMENTS OF CASH FLOWS (unaudited)(continued)
-----------------------------------------------
<TABLE>
<CAPTION>
For the Six Months Ended June 30,
------------------------------------
2000 1999
----------- -----------
<S> <C> <C>
Reconciliation of net income to net
cash used by operating activities:
Net income $1,849,844 123,592
Adjustments to reconcile net income
to net cash used by operating
activities:
Net realized (gain) loss from sales
of equity investments (3,402,598) 30,464
Realized gain from venture
capital limited partnership
investments (680,264) (126,968)
Realized losses from investment
write-downs -- 2,615
Change in net unrealized fair value:
Equity investments 765,033 (688,448)
Notes receivable 971,979 --
Changes in:
Due to related parties (46,842) 89,597
Accrued interest on notes receivable (289,331) --
Accounts payable and accrued expenses (27,421) --
Other changes, net (8,286) 2,349
--------- -------
Net cash used by operating activities $ (867,886) (566,799)
========= =======
</TABLE>
See accompanying notes to unaudited financial statements.
<PAGE>
NOTES TO FINANCIAL STATEMENTS (unaudited)
----------------------------------------
1. General
-------
Interim Financial Statements
----------------------------
In the opinion of the Managing General Partners, the accompanying interim
financial statements reflect all adjustments necessary for a fair
presentation of the financial position, results of operations, and cash
flows for the interim periods presented. These statements should be read
in conjunction with the Annual Report on Form 10-K for the year ended
December 31, 1999. Allocation of income and loss to Limited and General
Partners is based on cumulative income and loss. Adjustments, if any, are
reflected in the current quarter balances.
Valuation of Investments
------------------------
Investments are valued at fair value as required by the Investment Company
Act of 1940.
The Management Committee has the authority to establish valuation
procedures and periodically apply such procedures to the Partnership's
venture capital investment portfolio. In fulfilling this responsibility,
the Managing General Partners under the direction of the Management
Committee periodically update and revise the valuation procedures used to
determine fair value in order to reflect new events, changing market
conditions, more experience with investee companies, or additional
information, any of which may require the revision of previous estimating
procedures. Any change in fair value which results from the revision in
estimating procedures is reported as a change in accounting estimate. The
valuation procedures have been revised and approved by the Management
Committee and applied under their direction by the Managing General
Partners in preparing the June 30, 2000 financial statements. A change in
accounting estimate of $10,114,792 was recognized during the quarter ended
June 30, 2000 to reflect the revisions to the valuation and is included in
the "Change in net unrealized fair value of investments" on the Statement
of Operations.
The fair value of investments in publicly traded securities is considered
to be the amount which the company may reasonably expect to receive if sold
on the valuation date. Unrestricted securities are valued at the five-day
average closing sales price or bid/ask price that is available on a
national securities exchange or over-the-counter market. Valuation
discounts of 5% to 50% are applied to securities subject to resale
restrictions resulting from Rule 144, contractual lock-ups such as those
commonly associated with underwriting agreements, or knowledge of material
non-public information and also to unrestricted securities when the number
of shares held by the Partnership and its affiliates is substantial in
relation to the average trading volume.
The fair value of all other investments is determined in good faith by the
Managing General Partners under the direction of the Management Committee
after consideration of available, relevant information. There is no ready
market for the Partnership's investments in private companies or
unregistered securities of public companies. Fair value is generally
defined as the amount the Partnership could reasonably expect to receive
for an investment in an orderly disposition on a current sale. Inherent in
the good faith determination of fair value of these investments is the
selection of a reasonable period for orderly disposition. As the
Partnership nears the end of its life, the available period for disposition
necessarily shortens. Other significant factors considered in the
estimation of fair value include the inherent illiquidity of and lack of
marketability associated with venture capital investments in private
companies or unregistered securities, the investee company's enterprise
value established in the last round of venture financing, changes in market
conditions since the last round of venture financing or since the last
reporting period, the value of a minority interest in the investee company,
contractual restrictions on resale typical of venture financing
instruments, the investee company's financial position and ability to
obtain any necessary additional financing, the investee company's
performance as compared to its business plan, and the investee company's
progress towards initial public offering. The values determined for the
Partnership's investments in these securities are based upon available
information at the time the good faith valuations are made and do not
necessarily represent the amount which might ultimately be realized which
could be higher or lower than the reported fair value.
At June 30, 2000 and December 31, 1999, the investment portfolio included
investments totaling $5,354,621 and $9,113,523, respectively, whose fair
values were established in good faith by the Managing General Partners
under the direction of the Management Committee in the absence of readily
ascertainable market values. In addition, investments in publicly traded
securities which have been subjected to a discount for legal, contractual
or practical restrictions as determined by the Management Committee
amounted to $8,586,330 and $3,154,600 at June 30, 2000 and December 31,
1999, respectively. Because of the inherent uncertainty in the valuation,
the values may differ significantly from the values that would have been
used had a ready market for the securities existed, and the differences
could be material.
2. Related Party Transactions
--------------------------
Related party costs are included in costs and expenses shown on the
Statements of Operations. Related party costs for the six months ended
June 30, 2000 and 1999, were as follows:
<TABLE>
<CAPTION>
2000 1999
-------- --------
<S> <C <C>
Management fees $117,051 83,070
Individual General Partners' compensation 23,728 20,006
Reimbursable operating expenses 470,935 354,076
</TABLE>
Certain reimbursable expenses have been accrued based upon interim
estimates prepared by the Managing General Partners and are adjusted to
actual periodically. There was $3,705 due from related parties at June 30,
2000 related to such expenses compared to $55,605 due to related parties at
December 31, 1999.
Amounts payable for management fees were $25,417 and $12,949 at June 30,
2000, and December 31, 1999, respectively. Pursuant to the Partnership
Agreement, quarterly management fees are equal to one quarter of one
percent of the fair value of Partnership assets.
Officers of the Managing General Partners occasionally receive stock
options as compensation for serving on the Boards of Directors of portfolio
companies. It is the Managing General Partners' policy that all such
compensation be transferred to the investing partnerships. If the options
are non-transferable, they are not recorded as an asset of the Partnership.
Any profit from the exercise of such options will be transferred if and
when the options are exercised and the underlying stock is sold by the
officers. Any such profit is allocated amongst the Partnership and
affiliated partnerships based upon their proportionate investment in the
portfolio company. At June 30, 2000, the Partnership had an indirect
interest in non-transferable Thermatrix Inc. options at an exercise price
higher than the current market value. At June 30, 2000, the Partnership
and affiliated partnerships had an indirect interest in non-transferable
Physiometrix, Inc., Endocare, Inc. and Genstar Therapeutics Corporation
options with a fair market value of $277,935.
<PAGE>
3. Equity Investments
------------------
<TABLE>
At June 30, 2000, equity investments consisted of:
<CAPTION>
June 30, 2000
Principal ----------------------
Amount or
Investment Shares as of Cost Fair
Industry (1)/Company Position Date June 30, 2000 Basis Value
-------------------- -------- ---------- ------------- ------- -------
<S> <C> <C> <C> <C> <C>
Communications--3.0%
--------------------
Efficient Networks, Common 1999-
Inc. shares 2000 1,901 315,257 120,476
VOIS, Other
Inc. investment 1999 $7,966 7,966 0
Women.com Networks, Common 1996-
Inc. shares 1999 148,696 518,955 383,635
---------- ----------
842,178 504,111
---------- ----------
Computer Equipment, Systems and Software--0.0%
----------------------------------------------
Ascent Logic Preferred
Corporation (a) shares 1992 106,383 99,000 3,723
Ascent Logic Common
Corporation (a) shares 1997 36,443 23,795 1,276
Reflection Common share
Technology, warrant
Inc. (a) at $0.50;
expiring
2001 1996 359,750 0 0
---------- ----------
122,795 4,999
---------- ----------
Environmental--5.9%
-------------------
SunPower Preferred 1990-
Corporation (a) shares 1994 1,013,637 1,179,051 988,296
Thermatrix Inc. Common
(b) shares 1996 1,105,847 3,095,533 0
Triangle
Biomedical Common
Sciences, Inc.(a) shares 1999 366 10,248 2,562
Triangle Common share
Biomedical warrant
Sciences, Inc.(a) at $28.00;
expiring
2009 1999 366 366 92
---------- ----------
4,285,198 990,950
---------- ----------
Information Technology--5.6%
----------------------------
WorldRes, Inc. Preferred 1997-
(a) (b) shares 1999 155,918 619,687 905,884
WorldRes, Inc. Preferred
(a) (b) share
warrants
at $3.70-
$4.63;
expiring 1997-
2002-2003 1999 9,721 82 35,035
---------- ----------
619,769 940,919
---------- ----------
Medical/Biotechnology--58.0%
----------------------------
ADESSO Specialty
Services
Organization Preferred 1997-
Inc. (a) (b) shares 2000 131,265 1,205,257 1,102,626
Biex, Inc. (a) (b) Preferred 1993-
shares 1999 777,021 1,023,540 204,707
Biex, Inc. (a) (b) Preferred
share
warrants
at $2.50;
expiring 1998-
2003 1999 59,653 0 0
ConjuChem Inc. (a) Preferred
share
warrants
at exercised aggregate
price TBD; purchase
expiring price
2001 1996 $13,495 0 0
Endocare, Inc. (b) Common 1996-
shares 1998 46,014 152,624 419,602
Endocare, Inc. (b) Common
share
warrant
at $3.00;
expiring
2001 1996 3,750 0 28,571
Genstar
Therapeutics Common
Corporation (b) share 1999 438,366 320,242 1,364,414
Genstar Common
Therapeutics share
Corporation (b) warrants at
$0.30-$0.74;
expiring
2005-2006 1999 291,667 0 836,564
Intella
Interventional Common
Systems, Inc. (a) shares 1993 584 0 0
Intella
Interventional Preferred
Systems, Inc. (a) shares 1993 304 0 0
Molecular
Geriatrics Common
Corporation (a) shares 1993 23,585 125,000 16,510
Periodontix, Preferred
Inc. (a) shares 1998 106,122 259,999 95,510
Peridontix, Convertible
Inc. (a) note (2) 1999 $37,000 40,642 16,257
Periodontix, Common
Inc. (a) share
warrants
at $2.25;
expiring 1999-
2004-2006 2000 6,167 0 0
Physiometrix, Common
Inc. (b) shares 1996 270,791 490,025 5,553,544
Sanarus
Medical, Preferred 1999-
Inc. (a) (b) shares 2000 106,666 160,000 64,000
---------- ----------
3,777,329 9,702,305
---------- ----------
Microelectronics--0.7%
----------------------
KOR Electronics, Preferred 1989-
Inc. (a) shares 1995 3,571,024 1,130,390 113,039
---------- ----------
1,130,390 113,039
---------- ----------
Retail/Consumer Products--0.0%
------------------------------
Yes! Entertainment Common
Corporation shares 1995 66,666 0 0
---------- ----------
0 0
---------- ----------
Venture Capital Limited Partnership Investments--12.4%
------------------------------------------------------
El Dorado Ltd.
Ventures III, L.P. Partnership
(a) interests various $250,000 212,460 1,073,254
Medical Science Ltd.
Partners, L.P. Partnership
(a) interests various $500,000 187,246 136,386
Newtek Ltd.
Ventures II, L.P. Partnership
(a) interests various $859,914 330,328 725,437
Onset Enterprises Ltd.
Associates, L.P. Partnership
(a) interests various $500,000 45,000 82,530
Utah Ventures Ltd.
Limited Partnership
Partnership (a) interests various $250,000 41,123 59,258
---------- ----------
816,157 2,076,865
---------- ----------
Total equity investments--85.6% $11,593,816 14,333,188
========== ==========
Legends and footnotes:
-- No investment held at end of period.
0 Investment active with a carrying value or fair value of zero.
(a) Equity security acquired in a private placement transaction; resale may be subject to certain
selling restrictions.
(b) Portfolio company is an affiliate of the Partnership; resale may be subject to certain
selling restrictions.
(1) Represents the total fair value of a particular industry segment as a percentage of Partners'
Capital at 06/30/00.
(2) The Partnership has no income-producing equity investments except for convertible and
subordinated notes which include accrued interest. Interest rates on such notes are 8%.
</TABLE>
All investments are valued at fair value as determined in good faith by the
Managing General Partners. See Note 1--Valuation of Investments.
Significant purchases and sales of investments during the six months ended
June 30, 2000 are as follows:
ADESSO Specialty Services Organization, Inc.
--------------------------------------------
In March 2000, the Partnership purchased 12,218 Series E Preferred shares
for $205,262.
CV Therapeutics, Inc.
---------------------
In January 2000, the Partnership sold its entire investment in the company
for proceeds of $239,383 and realized a gain of $130,603.
Efficient Networks, Inc.
------------------------
In February 2000, the Partnership sold 951 shares in the company for
proceeds of $109,365 and realized a gain of $34,111.
Genstar Therapeutics Corporation
--------------------------------
In March 2000, the company changed its name from UroGen Corp. to Genstar
Therapeutics Corporation.
Inhale Therapeutic Systems, Inc.
--------------------------------
In March 2000, the Partnership sold its entire investment in the company
for proceeds of $3,450,754 and realized a gain of $2,840,756.
Pharmos Corporation
-------------------
In January 2000, the Partnership sold its entire investment in the company
for proceeds of $191,382 and realized a gain of $146,134.
Pilot Network Services, Inc.
----------------------------
In February 2000, the Partnership sold its entire investment in the company
for proceeds of $298,760 and realized a gain of $181,379.
Sanarus Medical, Inc.
---------------------
In February 2000, the Partnership purchased an additional 73,333 Series A
Preferred shares for $110,000.
Venture Capital Limited Partnerships
------------------------------------
The Partnership made an additional investment of $26,150 in venture capital
limited partnerships in January 2000. The Partnership received cash
distributions totaling $218,819 from El Dorado Ventures III, L.P., Medical
Sciences Partners, L.P., Newtek Ventures II, L.P. and Utah Ventures Limited
Partnership, $28,182 of which were recorded as returns of capital and the
remaining recorded as realized gains. The Partnership received stock
distributions of Efficient Networks, Inc. and Medarex, Inc. with fair
values of $315,257 and $174,370, respectively. These distributions were
recorded as realized gains. The Partnership recorded an $858,342 net
increase in fair value as a result of increases in the fair value of the
underlying investments of the partnerships.
Marketable Equity Securities
----------------------------
At June 30, 2000, marketable equity securities had aggregate costs of
$2,623,562 and aggregate market values of $10,128,444. The net unrealized
gains at June 30, 2000 included gross gains of $8,476,206.
Subsequent Events
-----------------
In July 2000, the Partnership sold 143,387 common shares in Physiometrix,
Inc. for proceeds of $3,835,600 and realized a gain of $3,415,639.
Subsequent to June 30, 2000, the fair value of the Partnership's investment
in Genstar Therapeutics Corporation increased by $647,904 as a result of an
increase in the publicly traded market price on August 11, 2000.
4. Notes Receivable, net
---------------------
Activity from January 1 through June 30 consisted of:
<TABLE>
2000 1999
-------- --------
<S> <C> <C>
Balance at January 1 $ 221,307 202,777
Notes receivable issued 2,500,000 183,333
Repayments of notes receivable (6,836) (198,844)
Change in interest receivable 287,856 1,973
Change in allowance for loan losses (971,979) --
--------- -------
Total notes receivable,
net at June 30 $2,030,348 189,239
========= =======
</TABLE>
The interest rate on notes receivable at June 30, 2000 ranged from 8.5% to
50%. All notes are due on demand.
In 2000, the Partnership recorded a $971,979 decrease in the fair value of
notes receivable from a portfolio company in the computer equipment
industry based on the fair value of the notes as determined in good faith
by the Managing General Partners.
Subsequent to June 30, 2000, the Partnership funded an additional
$1,500,000 to Sutmyn Storage Corporation in exchange for secured notes
receivable.
5. Cash and Cash Equivalents
-------------------------
Cash and cash equivalents at June 30, 2000 and December 31, 1999 consisted
of:
<TABLE>
2000 1999
------ ------
<S> <C> <C>
Demand accounts $ -- 151,868
Money-Market accounts 407,775 525,417
------- -------
Total 407,775 677,285
======= =======
</TABLE>
6. Distributions
-------------
In the quarter ended June 30, 2000, a quarterly tax distribution totaling
$1,314,295 was declared and paid to the General Partners.
7. Short-Term Borrowings
---------------------
The Partnership has a borrowing account with a financial institution. At
June 30, 2000, the borrowing capacity of this account, which fluctuates
based on collateral value, was $419,601 and there were no outstanding
borrowings. Interest is charged at the prime rate plus one-half percent.
The Partnership's investment in Endocare, Inc. is pledged as collateral.
8. Commitments and Contingencies
-----------------------------
The Partnership is a party to financial instruments with off-balance-sheet
risk in the normal course of its business. Generally, these instruments
are commitments for future equity fundings, venture capital limited
partnership investments, equipment financing commitments, or accounts
receivable lines of credit that are outstanding but not currently fully
utilized. As they do not represent current outstanding balances, these
unfunded commitments are properly not recognized in the financial
statements. At June 30, 2000, unfunded investment commitments to portfolio
companies totaled $2,100,000.
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Financial Condition, Liquidity and Capital Resources
----------------------------------------------------
The Partnership operates as a business development company under the
Investment Company Act of 1940 and makes venture capital investments in new
and developing companies. The Partnership's financial condition is
dependent upon on the success of the portfolio companies. There is no
ready market for many of the Partnership's investments. It is possible
that some of its venture capital investments may be a complete loss or may
be unprofitable and that others will appear likely to become successful,
but may never realize their potential. The valuation of the Partnership's
investments in securities for which there are no available market quotes is
subject to the estimate of the Managing General Partners in accordance with
the valuation guidance described in Note 1 to the financial statements. In
the absence of readily obtainable market values, the estimated fair value
of the Partnership's investments may differ significantly from the values
that would have been used had a ready market existed.
During the six months ended June 30, 2000, net cash used by operating
activities totaled $867,886. The Partnership paid management fees of
$104,583 to the Managing General Partners and reimbursed related parties
for operating expenses of $530,245 in 2000. In addition, $23,728 was paid
to the Individual General Partners as compensation for their services.
Other operating expenses of $223,156 were paid, interest paid on short-term
borrowings was $3,732 and interest income of $17,558 was received.
During the six months ended June 30, 2000, the Partnership funded equity
investments of $350,617 primarily to portfolio companies in the
medical/biotechnology industry and issued $2,500,000 in notes receivable to
a portfolio company in the computer equipment, systems and software
industry. Proceeds from the sales of equity investments were $4,537,633
and repayments of notes receivable were $6,836. At June 30, 2000, the
Partnership's unfunded commitments totaled $2,100,000.
In the quarter ended June 30, 2000, the Partnership declared and paid
$1,314,295 in General Partner tax distributions.
Cash and cash equivalents at June 30, 2000, were $407,775. Interest income
on short-term investments and future proceeds from investment sales are
expected to be adequate to fund Partnership operations through the next
twelve months.
Results of Operations
---------------------
Current quarter compared to corresponding quarter in the preceding year
-----------------------------------------------------------------------
Net loss was $12,353,250 for the quarter ended June 30, 2000, compared to
net income of $1,043,196 during the same period in 1999. The change was
primarily due to a decrease of $12,800,061 in the net unrealized fair value
of equity investments, a $971,979 decrease in the net unrealized fair value
of notes receivable and a $109,663 increase in operating expenses,
partially offset by a $270,334 increase in net realized gain from venture
capital limited partnerships and a $254,969 increase in interest income.
During the quarter ended June 30, 2000, the decrease in equity investment
fair value of $11,447,839 was primarily attributable a $9,142,813 decrease
in fair value of equity investments for the change in accounting estimate
discussed in Note 1 to the financial statements. Additional decreases in
fair value resulted from decreases in portfolio companies in the
communications, environmental and medical/biotechnology industries. During
the same period in 1999, the increase in fair value of equity investments
of $1,352,222 was primarily attributable to increases in portfolio
companies in the communications and environmental industries, partially
offset by decreases in portfolio companies in the medical/biotechnology
industry.
During the quarter ended June 30, 2000, the Partnership recorded a decrease
in the fair value of notes receivable of $971,979 for the change in
accounting estimate discussed in Note 1 to the financial statements. There
was no such amount recorded for the same period in 1999.
Total operating expenses were $437,132 and $327,469 for the quarters ended
June 30, 2000 and 1999, respectively. In the second quarter of 2000, the
Managing General Partners billed the Partnership an additional $170,464 for
investment management expenses incurred by the General Partners in 1998 and
1999, but not previously billed to the Partnership. If these expenses had
been billed in prior years, operating expenses for the three months ended
June 30, 2000 and 1999 would have been $266,668 and $351,429, respectively.
The decrease is attributable to decreased investment activity and the
related administrative costs.
During the quarter ended June 30, 2000, the Partnership recorded net
realized gains from venture capital limited partnership investments of
$331,026. During the same period in 1999, there were gains of $60,692.
The gains represented distributions from profits of venture capital limited
partnerships.
For the quarter ended June 30, 2000, interest income of $267,057 was
primarily the result of interest earned on secured notes receivable.
During the same period in 1999, interest income was $12,088.
Given the inherent risk associated with the business of the Partnership,
the future performance of the portfolio company investments may
significantly impact future operations.
Current six months compared to corresponding six months in the
--------------------------------------------------------------
preceding year
--------------
Net income was $1,849,844 and $123,592 for the six months ended June 30,
2000 and 1999, respectively. The change was primarily due to an increase of
$3,433,062 in the net realized gain from sales of equity investments, a
$553,296 increase in net realized gain from venture capital limited
partnerships and a $278,385 increase in interest income, partially offset
by a $1,453,481 decrease in the net unrealized fair value of equity
investments, a $971,979 decrease in the net unrealized fair value of notes
receivable and a $77,943 increase in operating expenses.
Net realized gain from sales of equity investments was $3,402,598 for the
six months ended June 30, 2000, as compared to a net realized loss of
$30,464 for the six months ended June 30, 1999. The gain in 2000 primarily
related to the sale of Inhale Therapeutic Systems, Inc. (See Note 3.) The
loss in 1999 resulted from the sale of Endocardial Solutions, Inc.
During the six months ended June 30, 2000, the Partnership recorded net
realized gains from venture capital limited partnership investments of
$680,264. During the same period in 1999, there were gains of $126,968.
The gains represented distributions from profits of venture capital limited
partnerships.
For the quarter ended June 30, 2000, interest income of $306,889 was
primarily the result of interest earned on secured notes receivable.
During the same period in 1999, interest income was $28,504.
During the six months ended June 30, 2000, the decrease in equity
investment fair value of $765,033 was mainly attributable to a $9,142,813
decrease in fair value of equity investments for the change in accounting
estimate discussed in Note 1 to the financial statements and decreases in
portfolio companies in the communications and environmental industries.
This decrease was partially offset by increases in portfolio companies in
the medical/biotechnology industry and the venture capital limited
partnerships. During the same period in 1999, the increase of $688,448 was
primarily attributable to portfolio companies in the communications and
information technology industries, partially offset by decreases in the
microelectronics industry.
During the six months ended June 30, 2000, the Partnership recorded a
decrease in the fair value of notes receivable of $971,979 for the change
in accounting estimate discussed in Note 1 to the financial statements.
There was no such amount recorded for the same period in 1999.
Total operating expenses were $662,116 and $584,173 for the six months
ended June 30, 2000 and 1999, respectively. In the second quarter of 2000,
the Managing General Partners billed the Partnership an additional $170,464
for investment management expenses incurred by the General Partners in 1998
and 1999, but not previously billed to the Partnership. If these expenses
had been billed in prior years, operating expenses for the six months ended
June 30, 2000 and 1999 would have been $491,652 and $629,026, respectively.
The decrease is attributable to decreased investment activity and the
related administrative costs.
II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) No reports on Form 8-K were filed by the Partnership during the
quarter ended June 30, 2000.
(b) Financial Data Schedule for the six months ended and as of
June 30, 2000 (Exhibit 27).
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized.
TECHNOLOGY FUNDING VENTURE PARTNERS IV,
AN AGGRESSIVE GROWTH FUND, L.P.
By: TECHNOLOGY FUNDING INC.
Managing General Partner
Date: August 14, 2000 By: /s/Charles R. Kokesh
-----------------------------------
Charles R. Kokesh
President, Chief Executive
Officer, Chief Financial
Officer and Chairman of
Technology Funding Inc. and
Managing General Partner of
Technology Funding Limited
